Understanding the spatial distribution of a drug candidate within the body is fundamental to predicting its efficacy and potential toxicity profile. Tissue distribution studies reveal the fate of compounds after administration, mapping their transport, accumulation, and elimination across specific organs and tissues. This data is vital for confirming target engagement and identifying potential off-target risks during the early drug discovery phase.
BOC Sciences offers comprehensive Tissue Distribution Services tailored for drug R&D. We utilize advanced bioanalytical techniques, including LC-MS/MS and Quantitative Whole-Body Autoradiography (QWBA), to provide high-resolution data on drug concentration in diverse tissues. Our discovery-grade studies help clients optimize lead compounds, assess blood-brain barrier (BBB) permeability, and evaluate tumor targeting efficiency, accelerating the selection of promising candidates.
We accurately measure drug concentrations in homogenized tissue samples using high-sensitivity LC-MS/MS or Ligand Binding Assays (LBA). This service provides precise pharmacokinetic (PK) data for specific organs, calculating tissue-to-plasma ratios to assess accumulation and exposure levels.
Utilizing radiolabeled compounds (14C, 3H), our Quantitative Whole-Body Autoradiography (QWBA) visualizes drug distribution across the entire animal. This holistic approach identifies unexpected accumulation sites and visualizes distribution patterns without the need for individual tissue dissection.
For detailed spatial resolution, we offer Micro-Autoradiography (MAR) and Mass Spectrometry Imaging (MSI). These techniques map drug distribution at the sub-organ or cellular level, essential for understanding intratumoral penetration or distribution within complex structures like the kidney or brain.
BOC Sciences delivers precise tissue distribution data to validate target exposure and predict safety profiles in early discovery.
The gold standard for small molecule quantification. We homogenize harvested tissues and utilize Liquid Chromatography (LC) with Tandem Mass Spectrometry to detect trace levels of parent drugs and major metabolites with high specificity and sensitivity.
By cryosectioning whole animal carcasses dosed with radiolabels, we generate high-resolution images of compound distribution. This method captures a snapshot of the drug in all tissues simultaneously, including those difficult to dissect (e.g., uveal tract, cartilage).
LSC provides robust quantification of total radioactivity in tissue homogenates. Often used alongside QWBA, it validates imaging data and provides mass balance information, ensuring a complete picture of drug recovery.
A label-free technique that maps the spatial distribution of drugs and metabolites directly on tissue sections. It is powerful for distinguishing parent drugs from metabolites within the same tissue slice without radioactive labeling.
For fluorescently labeled biologics or nanoparticles, we use optical imaging systems to track biodistribution in live animals over time. This longitudinal approach reduces animal usage and visualizes dynamic accumulation in regions of interest.
Designed for biologics like monoclonal antibodies and proteins. We utilize optimized ELISA or hybrid LBA/LC-MS workflows to quantify large molecules in tissue matrices, addressing challenges related to extraction efficiency and stability.
BOC Sciences adapts its bioanalytical strategies to accommodate the unique physicochemical properties and distribution kinetics of diverse therapeutic modalities.
Tell us about your compound and target indication. BOC Sciences will design a tailored tissue distribution study to map your drug's journey.
We collaborate to define time points, dose routes, and target tissues based on your compound's PK profile. We select the optimal detection method (LC-MS vs. Imaging).
Test compounds are administered to laboratory animals. Tissues are harvested at pre-defined intervals, weighed, and processed (homogenization or embedding).
Samples undergo rigorous bioanalysis. For QWBA, sections are exposed to phosphor screens; for LC-MS, concentrations are quantified against standard curves.
We deliver a data-rich report including tissue concentration vs. time profiles, AUC ratios (Tissue/Plasma), and heatmaps of distribution, aiding in candidate selection.
We offer high-throughput LC-MS/MS screening to rapidly assess tissue-to-plasma ratios. Our solution focuses on identifying metabolic hotspots and ensuring that lead compounds achieve sufficient exposure in target organs while avoiding excessive accumulation in elimination organs like the liver and kidneys.
Large molecules face unique distribution barriers. Our Ligand Binding Assay (LBA) and ELISA-based solutions are optimized to detect therapeutic proteins in complex tissue matrices, helping you understand target-mediated drug disposition (TMDD) and penetration into dense tissues such as solid tumors.
Tracking genetic cargo requires specialized techniques. We provide solutions combining RT-qPCR and hybridization assays to quantify tissue uptake of siRNA, ASOs, or mRNA. We map the biodistribution of viral vectors (e.g., AAV) to confirm tropism and rule out off-target transduction in germline tissues.
Understanding the fate of the carrier versus the payload is critical. Our solution employs dual-tracking methods, fluorescence imaging for the nanoparticle shell and bioanalysis for the active drug, to evaluate payload release kinetics, stability in circulation, and accumulation at the disease site.
Partner with our scientists to perform precise tissue distribution analysis across key organs. Gain actionable insights for informed development decisions.
Our optimized LC-MS/MS methods achieve lower limits of quantification (LLOQ), ensuring detection of compounds even in tissues with low penetration or high matrix interference.
By combining QWBA imaging with quantitative tissue excision, we provide a dual perspective: the "where" (spatial map) and the "how much" (exact concentration).
We have extensive experience processing challenging tissues such as bone marrow, ocular tissues, and lipid-rich organs, ensuring high recovery rates and accurate data.
Designed for the pace of discovery, our workflows are streamlined to deliver critical distribution data rapidly, keeping your lead optimization cycles short.
Client Needs: A biotech client needed to screen three lead compounds designed for Alzheimer's disease to select the one with the best Blood-Brain Barrier (BBB) permeability.
Challenges: Plasma PK looked similar for all three, but efficacy varied. The client needed to distinguish the compounds based on their unbound concentration in the brain, but lacked sensitive methods for brain tissue homogenization and extraction.
Solution: BOC Sciences executed a precision tissue distribution study. We harvested plasma, CSF, and micro-dissected brain regions (hippocampus and cortex). Our team developed a specialized protein precipitation extraction method followed by UHPLC-MS/MS analysis in MRM mode. This approach effectively removed lipid interferences and achieved an LLOQ of 0.5 ng/g, allowing for the accurate detection of trace compound levels in specific brain sub-regions.
Outcome: We identified that Compound B had a 3-fold higher brain-to-plasma ratio compared to the others. The data allowed the client to prioritize Compound B for further efficacy studies, saving resources on the less permeable candidates.
Client Needs: A developer of RNA therapeutics needed to verify if their Lipid Nanoparticle (LNP) formulation was effectively delivering the payload to the tumor rather than being sequestered in the liver.
Challenges: Standard plasma PK did not reflect tissue exposure. The client needed to visualize the biodistribution of the LNP carrier versus the payload in a tumor-bearing mouse model.
Solution: We designed a dual-modality tracking study. The LNP shell was labeled with a near-infrared fluorophore for whole-body optical imaging, while the RNA payload was quantified using RT-qPCR in excised tissue homogenates. Additionally, confocal microscopy was employed on tumor cryosections to verify cellular internalization. This comprehensive approach allowed us to distinguish between the distribution of the delivery vehicle and the functional release of the genetic cargo.
Outcome: The study revealed high tumor accumulation but significant liver uptake. This insight prompted the client to modify the lipid composition (PEGylation) to improve circulation time and tumor specificity in the next iteration.
Client Needs: A pharma company observed unexpected toxicity in a kidney cell line and needed to determine if their small molecule candidate was accumulating excessively in the renal cortex in vivo.
Challenges: Whole kidney analysis was insufficient as it diluted the signal. The client required spatial resolution to distinguish between the cortex and medulla accumulation.
Solution: BOC Sciences utilized Quantitative Whole-Body Autoradiography (QWBA). We administered a 14C-labeled radiotracer and prepared 30 µm whole-body cryosections. The sections were exposed to phosphor imaging plates for 48 hours and analyzed using a high-resolution scanner. By employing validated calibration standards, we were able to quantify radioactivity specifically in the renal cortex pixels, differentiating them from the medulla and collecting duct signals.
Outcome: Results confirmed 10x accumulation in the cortex relative to plasma. The data provided a clear mechanistic link to the observed toxicity, leading to a structural redesign of the compound to reduce renal transporter affinity.
Tissue distribution study aims to evaluate the distribution of a compound across various tissues and organs in the body. By quantifying drug or tracer concentrations in different tissues, it provides data for drug optimization, dosage design, and targeted delivery, helping researchers understand in vivo distribution characteristics and offering a scientific basis for development strategies.
Tissue distribution studies typically rely on highly sensitive analytical methods, such as LC-MS/MS, radiographic imaging, and fluorescent labeling. Technique selection should consider detection limits, tissue matrix interference, and sample handling challenges to ensure accurate and reliable quantification across different tissues and organs.
Sample handling is a critical aspect of tissue distribution studies. Due to tissue complexity, improper handling can lead to drug degradation or low recovery. Proper tissue homogenization, extraction, and storage strategies preserve compound integrity, ensuring accuracy and reproducibility of results, and providing reliable data for downstream interpretation.
By analyzing drug concentrations in each tissue and time-concentration profiles, targeting and selectivity can be assessed. High accumulation in target tissues with low exposure in non-target tissues suggests good targeting, whereas broad distribution may require further optimization. Such data provide direct guidance for delivery systems or structural modification strategies.
Optimization can focus on sample design, labeling method selection, and analytical sensitivity improvement. By optimizing sampling time points, enhancing detection sensitivity, and refining data processing, more precise tissue distribution information can be obtained, providing accurate data support for drug design, dosing strategies, and delivery system improvements.
The tissue distribution data provided by BOC Sciences was the turning point for our project. Seeing the actual accumulation in the target organ helped us confidently select our lead candidate. The LC-MS analysis was precise and the reporting was excellent.
— Dr. Arthur, Principal Scientist, Biotech Startup
We used their QWBA service to track our radiolabeled compound. The image quality was superb, revealing distribution patterns we hadn't predicted from plasma data alone. It gave us a true understanding of the drug's disposition.
— Dr. Liam, DMPK Lead, Pharmaceutical Company
We needed a quick study to check BBB penetration before an investor milestone. BOC Sciences accommodated our tight timeline and delivered robust brain-to-plasma ratio data that validated our platform.
— Dr. James, Director of Pharmacology, Neuro-focused Biotech
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
